Rachelle Hannon, APRN
Family · Hobart, INNPI 1245989797
Payments from drug & device makers
Across 109 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$535
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$238
- AstraZeneca$146
- Lilly USA, LLC$119
- Corium, LLC$118
- Novo Nordisk$116
- plus $841 from 17 others
What the payments were for
- Food & beverage$2,113100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 24 | $535 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $238 |
| AstraZeneca | 8 | $146 |
| Lilly USA, LLC | 6 | $119 |
| Corium, LLC | 6 | $118 |
| Novo Nordisk | 7 | $116 |
| Exact Sciences | 5 | $89 |
| Otsuka America Pharmaceutical, Inc. | 5 | $88 |
| Almatica Pharma LLC | 5 | $85 |
| Bayer | 4 | $74 |
| Xeris Pharmaceuticals, Inc. | 4 | $69 |
| Edwards Lifesciences | 1 | $67 |
| GSK | 4 | $60 |
| Novartis | 3 | $58 |
| Mylan Specialty L.p. | 3 | $56 |
| Merck | 3 | $55 |
| Dexcom, Inc. | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Amgen | 1 | $19 |
| Boehringer Ingelheim | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Itamar Medical Inc | 1 | $6 |
How this compares
$2,113 in reported general payments places this provider in the 80th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 36 | $47,832 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $38,675 |
| OzempicSemaglutide | 22 | $25,756 |
| CaplytaLumateperone Tosylate | 12 | $20,313 |
| FarxigaDapagliflozin Propanediol | 19 | $19,345 |
| WegovySemaglutide | 12 | $18,582 |
| TrulicityDulaglutide | 12 | $17,702 |
| MounjaroTirzepatide | 18 | $17,313 |
| JanuviaSitagliptin Phosphate | 11 | $16,553 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $7,247 |
| EliquisApixaban | 11 | $7,085 |
| Celecoxib | 25 | $2,093 |
| Duloxetine Hcl | 41 | $1,849 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 82 | $1,737 |
| Doxepin Hcl | 16 | $1,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $16 | $47,83236 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $60 | $45,92270 claims |
| Novo NordiskOzempic, Wegovy | $116 | $44,33934 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Olanzapine | $119 | $35,44843 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $238 | $20,31312 claims |
| AstraZenecaFarxiga | $146 | $19,34519 claims |
| MerckJanuvia | $55 | $16,55311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,392 family providers in Indiana.
Other family in Hobart
- Myra SikwataHobart$131K
- Jillian GreerHobart$18K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.